Therapy of chronic graft-versus-host disease

Mukta Arora

Research output: Contribution to journalReview articlepeer-review

13 Scopus citations


Chronic graft-versus-host disease (cGVHD) is a common complication after hematopoietic-cell transplant and remains the leading cause of late non-relapse mortality. Standard treatment includes a combination of a calcineurin inhibitor and corticosteroids. Prolonged steroid use is required, with more than 50% of patients continuing immunosuppression beyond 2 years. There is no standard second-line therapy for cGVHD. Many agents have been reported in small case series, but the studies are heterogeneous in patient selection and response criteria. There is a need for a systematic study of agents for secondary therapy of cGVHD. In addition, both cGVHD and its treatment are associated with severe complications, including life-threatening infections, reduced quality of life, and psychosocial disturbances. A multidisciplinary approach to evaluating and managing patients with cGVHD is preferred, and disciplined, prospective study of new therapies is essential to make further progress in its understanding and treatment.

Original languageEnglish (US)
Pages (from-to)271-279
Number of pages9
JournalBest Practice and Research: Clinical Haematology
Issue number2
StatePublished - Jun 2008
Externally publishedYes


  • BMT
  • cGVHD
  • chronic graft versus host disease
  • therapy


Dive into the research topics of 'Therapy of chronic graft-versus-host disease'. Together they form a unique fingerprint.

Cite this